News Europe European Cannabis THC Levels Have Doubled In 10 years

European Cannabis THC Levels Have Doubled In 10 years

-

THC levels in European cannabis have more than doubled in a decade with cannabis the most widely used ‘illicit’ drug in Europe, show recent research.

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) report shows that the THC (Tetrahydrocannabinol) concentration of ‘herbal cannabis’ doubled from 5% to 10%, from 2006 to 2016.

The report — Developments In The European Cannabis Market — provides an overview of emerging and established cannabis trends in Europe.

It says the global moves towards legalisation of recreational cannabis, and the wider adoption of cannabis as a medicine – are driving innovation.

This is leading to a surge in the development of new cannabis products, and some of these are now appearing in the European market.

The report calls for closer monitoring of the health effects of all cannabis products. EMCDDA Director Alexis Goosdeel said: “New and more potent cannabis products may have serious public health consequences for users. 

“Therefore, monitoring and understanding new trends in cannabis products available to European consumers today is important to inform the policy and regulatory debate.”

With concentrates, edibles, and CBD nutraceuticals now prevalent in Europe  the report calls for new monitoring tools and regulations. 

It says: “Having the ability to distinguish illicit cannabis products from cannabis-based medicinal products and unregulated CBD oils will be important for law enforcement in many jurisdictions.”

The report gores on to say that some 17.5 m Europeans, aged between 15–34, are estimated to have used cannabis in the last year, while one per cent of 1% of adults – aged between 15 and 64 years, use cannabis every day.

In 2017, some 155,000 people entered drug treatment in Europe for problems related to this drug, of those around 83,000 were entering treatment for the first time. 

Cannabis is now the substance most often named by new entrants to specialist drug treatment services as their main reason for contact in the 28-member states of the European Union, says the report.

Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

The UK Medical Cannabis Industry Can – And Does – Provide Epilepsy Medicines For Children In Post-Brexit Britain

Pierre Van Weperen of Grow Pharma on the post-Brexit issue surrounding the import of epilepsy cannabis medicines into the...

Dozens of CBD Brands In A State of ‘Absolute Panic’ With UK Novel Food Deadline Weeks Away

THE New Year has brought a realisation that the Novel Food deadline is less than three months away leading...

Work Gets Underway On Scotland’s First Medical Cannabis Cultivation and Production Facility

SCOTLAND’S first home-grown cannabis medicines could be in UK patients’ hands in early 2022 after work started on a...

Amazon Enters CBD Retail Market – But Only In One Country

GLOBAL on-line retail giant Amazon is dipping its toes into the CBD market with the first ever products now...

Markets: US Stocks Surge With Democrats’ Victory, Columbia Care, Sativa Wellness, Cann Group et al…

WITH the Democrats in control of the White House, Senate and Congress Wall Street now beckons for America's cannabis...

Channel Island Firm Secures Britain’s First High-THC Commercial Cultivation Licence For Over 20 Years

CHANNEL islands company Northern Leaf has successfully secured a medical cannabis cultivation licence to produce medicines for the UK...

Must read

You might also likeRELATED
Recommended to you